文献速递甲状腺疾病

T3在甲状腺功能减退症管理中的相关性

The relevance of T3 in the management of hypothyroidism.
PubMed 文献 · Lancet Diabetes Endocrinol · 2022-02-28

左甲状腺素单药治疗甲状腺功能减退症已超过40年,但患者血清三碘甲状腺原氨酸(T3)浓度相对较低,部分患者即使促甲状腺激素(TSH)正常化后症状仍持续。本文探讨识别可考虑左甲状腺素联合碘塞罗宁补充患者的可行性,并提及基因谱分析作为未来工具及新型缓释碘塞罗宁制剂正在研发中。

要点

  • 左甲状腺素治疗患者血清T3浓度相对较低,部分患者TSH正常化后症状仍持续。
  • 维持正常T3浓度是甲状腺轴优先事项,临床关注点转向血清T3浓度。
  • 基因谱分析是识别因外周T4活化不佳而对左甲状腺素反应欠佳患者的潜在未来工具。

核心结论

  • 本文探讨当前是否可识别可考虑左甲状腺素联合碘塞罗宁补充的患者,并指出基因谱分析是识别因外周T4活化不佳而对左甲状腺素反应欠佳患者的潜在未来工具,新型缓释碘塞罗宁制剂正研发中拟在这些有症状患者中试验以恢复T3浓度并为T4加T3联合治疗提供确证性结果。

研究设计与样本

  • 本文为个人观点(Personal View)文章,探讨T3在甲状腺功能减退症管理中的相关性。

主要发现

  • 左甲状腺素单药治疗甲状腺功能减退症已超过40年,但接受左甲状腺素治疗的患者血清T3浓度相对低于一般人群。
  • 部分甲状腺功能减退症患者尽管TSH浓度正常化,症状仍持续。
  • 维持正常T3浓度是甲状腺轴的优先事项,这一认识已将临床关注点转向甲状腺功能减退症患者的血清T3浓度。
  • 基因谱分析是识别因外周T4活化不佳而对左甲状腺素反应欠佳患者的潜在未来工具。
  • 新型缓释碘塞罗宁制剂正在研发中,拟在这些有症状患者中进行试验,以尝试恢复T3浓度并为T4加T3联合治疗的使用提供确证性结果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Levothyroxine monotherapy has been the standard of care for treatment of hypothyroidism for more than 40 years. However, patients treated with levothyroxine have relatively lower serum tri-iodothyronine (T3) concentrations than the general population, and symptoms of hypothyroidism persist for some patients despite normalisation of thyroid-stimulating hormone (TSH) concentrations. The understanding that maintenance of normal T3 concentrations is the priority for the thyroid axis has redirected the clinical focus to serum T3 concentrations in patients with hypothyroidism. This Personal View explores whether it is currently feasible to identify patients who could be considered for liothyronine supplementation in combination with levothyroxine. Genetic profiling stands out as a potential future tool to identify patients who do not respond well to levothyroxine due to suboptimal peripheral thyroxine (T4) activation. Moreover, new slow-release liothyronine preparations are being developed to be trialled in these symptomatic patients, in an attempt to restore T3 concentrations and provide conclusive results for the use of T4 plus T3 combination therapy.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Salvatore D, Porcelli T, Ettleson MD, et al. The relevance of T3 in the management of hypothyroidism. Lancet Diabetes Endocrinol. 2022. PMID: 35240052. doi:10.1016/S2213-8587(22)00004-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。